198,470 Shares in MacroGenics, Inc. $MGNX Acquired by Nuveen LLC

Key Points

• Nuveen LLC acquired approximately 198,470 shares of MacroGenics, Inc., valued at around $252,000, representing a 0.31% ownership stake.
• MacroGenics stock has seen a 3.1% increase recently, with a current price of $2.00 after fluctuating between a 12-month low of $0.99 and a high of $5.10.
• A recent quarterly earnings report showed a loss of ($0.57) EPS, slightly beating expectations, but the revenue of $22.24 million fell short of the anticipated $28.06 million.

Nuveen LLC purchased a new stake in shares of MacroGenics, Inc. (NASDAQ:MGNX - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 198,470 shares of the biopharmaceutical company's stock, valued at approximately $252,000. Nuveen LLC owned about 0.31% of MacroGenics as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently modified their holdings of MGNX. ProShare Advisors LLC grew its holdings in shares of MacroGenics by 32.4% during the fourth quarter. ProShare Advisors LLC now owns 20,284 shares of the biopharmaceutical company's stock valued at $66,000 after buying an additional 4,963 shares during the last quarter. Wells Fargo & Company MN grew its holdings in shares of MacroGenics by 45.4% during the 4th quarter. Wells Fargo & Company MN now owns 29,838 shares of the biopharmaceutical company's stock valued at $97,000 after purchasing an additional 9,312 shares during the last quarter. Exchange Traded Concepts LLC grew its holdings in MacroGenics by 19.7% in the 1st quarter. Exchange Traded Concepts LLC now owns 58,434 shares of the biopharmaceutical company's stock worth $74,000 after acquiring an additional 9,611 shares during the last quarter. Lazard Asset Management LLC purchased a new stake in shares of MacroGenics in the 4th quarter worth about $32,000. Finally, Barclays PLC lifted its position in shares of MacroGenics by 13.3% in the 4th quarter. Barclays PLC now owns 111,891 shares of the biopharmaceutical company's stock worth $363,000 after purchasing an additional 13,138 shares during the period. Institutional investors own 96.89% of the company's stock.

MacroGenics Trading Down 0.9%

Shares of NASDAQ MGNX traded down $0.02 during mid-day trading on Wednesday, reaching $1.72. The company had a trading volume of 258,769 shares, compared to its average volume of 925,498. The business's 50-day moving average is $1.61 and its 200-day moving average is $1.62. The stock has a market cap of $108.41 million, a price-to-earnings ratio of -3.03 and a beta of 1.63. MacroGenics, Inc. has a 52 week low of $0.99 and a 52 week high of $5.10.

MacroGenics (NASDAQ:MGNX - Get Free Report) last issued its earnings results on Thursday, August 14th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.02. MacroGenics had a negative net margin of 21.99% and a negative return on equity of 40.24%. The company had revenue of $22.24 million for the quarter, compared to analysts' expectations of $28.06 million. As a group, equities research analysts forecast that MacroGenics, Inc. will post -1.06 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Wall Street Zen cut shares of MacroGenics from a "hold" rating to a "sell" rating in a report on Saturday, August 2nd. B. Riley decreased their target price on shares of MacroGenics from $5.00 to $3.00 and set a "neutral" rating for the company in a report on Tuesday, May 20th. Barclays reaffirmed an "overweight" rating and issued a $3.00 target price (down from $8.00) on shares of MacroGenics in a report on Wednesday, May 14th. Stifel Nicolaus decreased their target price on shares of MacroGenics from $6.00 to $5.00 and set a "hold" rating for the company in a report on Wednesday, May 14th. Finally, Leerink Partners reduced their price target on shares of MacroGenics from $8.00 to $5.00 and set an "outperform" rating for the company in a research note on Friday, August 15th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $3.60.

Insider Activity at MacroGenics

In other news, Director William K. Heiden purchased 49,500 shares of the firm's stock in a transaction on Wednesday, August 20th. The stock was acquired at an average cost of $1.49 per share, with a total value of $73,755.00. Following the completion of the transaction, the director owned 111,000 shares in the company, valued at $165,390. This represents a 80.49% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 13.00% of the company's stock.

About MacroGenics

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.